RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and maintains $55 price target.
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.